You are here: Welcome to the MPKB » Welcome to the MPKB » Resources for patients » Introduction to the Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:patients:protocol_overview [06.21.2019] – [Introduction to the Marshall Protocol] sallieqhome:patients:protocol_overview [06.24.2019] – [Introduction to the Marshall Protocol] sallieq
Line 6: Line 6:
  
 The Marshall Protocol, sometimes referred to as the MP, was developed by a team led by Trevor Marshall, PhD, as an antimicrobial treatment for chronic inflammatory diseases. Most diseases of unknown cause are chronic inflammatory diseases, and almost 100% of patients with these diseases have responded to the treatment. On this site and others, chronic inflammatory diseases are sometimes referred to as the Th1 diseases. The Marshall Protocol, sometimes referred to as the MP, was developed by a team led by Trevor Marshall, PhD, as an antimicrobial treatment for chronic inflammatory diseases. Most diseases of unknown cause are chronic inflammatory diseases, and almost 100% of patients with these diseases have responded to the treatment. On this site and others, chronic inflammatory diseases are sometimes referred to as the Th1 diseases.
 +
 +Treatment on the MP requires a [[home:patients:mp_duration|number of years]] to complete, but the exact duration is determined by degree of illness and any unavoidable immune suppressants to which the patient is exposed.
  
 At its essence, the MP involves five key elements, each of which is supported by the [[home:protocol|latest insights]] in molecular science. MP patients must: At its essence, the MP involves five key elements, each of which is supported by the [[home:protocol|latest insights]] in molecular science. MP patients must:
  
   1 take a minimum 40mg olmesartan (Benicar) every 4-6 hours;   1 take a minimum 40mg olmesartan (Benicar) every 4-6 hours;
-  2 avoid as far as possible stress and environmental immune suppression such as radio frequency radiation;    +  2 avoid inter-personal stress and environmental immune suppression such as radio frequency radiation;    
-  3 avoid the consumption of vitamin D, as well as certain other immunosuppressive [[home:food|foods]];   +  3 avoid the consumption of vitamin D, as well as certain other immunosuppressive foods;   
-  4 wean off any immunosuppressive or potentially immunosuppressive [[home:othertreatments|therapies]]; +  4 wean off any immunosuppressive or potentially immunosuppressive therapies; 
-  5 [[home:lifestyle:light|manage exposure to light]], depending on blood levels of vitamin D and photosensitivity (if experienced)+  5 manage exposure to light, depending on blood levels of vitamin D and photosensitivity (if experienced)
  
  
Line 22: Line 24:
 The objective of the MP is to safely activate a [[home:pathogenesis:innate_immunity#antimicrobial_peptides|highly versatile]] defense, the innate immune response. By strengthening the innate immune response, the MP targets the mix of microbes including bacteria, fungi, and viruses that play a role in chronic disease. As pathogens and infected human cells die, they generate inflammation (sometimes called a "cytokine storm") and release endotoxins into the body, resulting in a temporary increase in patients' original symptoms. This is known as immunopathology (generally abbreviated to IP). The objective of the MP is to safely activate a [[home:pathogenesis:innate_immunity#antimicrobial_peptides|highly versatile]] defense, the innate immune response. By strengthening the innate immune response, the MP targets the mix of microbes including bacteria, fungi, and viruses that play a role in chronic disease. As pathogens and infected human cells die, they generate inflammation (sometimes called a "cytokine storm") and release endotoxins into the body, resulting in a temporary increase in patients' original symptoms. This is known as immunopathology (generally abbreviated to IP).
  
-Treatment on the MP requires a [[home:patients:mp_duration|number of years]] to complete, but the exact duration is determined by degree of illness and any unavoidable immune suppressants to which the patient is exposed. 
  
 The MP is to be administered only by a [[home:starting:physician|licensed physician]] competent in use of the Marshall Protocol. The available evidence for the treatment's effectiveness is [[home:physicians:concerns#concerns_about_lack_of_clinical_evidence|described here]]. The MP is to be administered only by a [[home:starting:physician|licensed physician]] competent in use of the Marshall Protocol. The available evidence for the treatment's effectiveness is [[home:physicians:concerns#concerns_about_lack_of_clinical_evidence|described here]].
home/patients/protocol_overview.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.